These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 4581374)

  • 1. Dexetimide (R 16470) in the control of neuroleptic-induced extrapyramidal side-effects. Its prophylactic value and duration of action.
    Huygens H; Vereecken JL; Tanghe A
    Psychiatr Neurol Neurochir; 1973; 76(4):251-9. PubMed ID: 4581374
    [No Abstract]   [Full Text] [Related]  

  • 2. A quantitative study of neuroleptic-induced extrapyramidal symptoms and their response to dexetimide, a potent and long-acting antiparkinsonian agent.
    Dom R; Van Lommel R; Baro F
    Acta Psychiatr Scand; 1971; 47(4):399-410. PubMed ID: 4947805
    [No Abstract]   [Full Text] [Related]  

  • 3. Dexetimide: an effective drug for the control of extrapyramidal symptoms induced by pipothiazine palmitate.
    Dom R; Van Lommel R; Baro F
    Acta Psychiatr Scand; 1973; 49(5):563-9. PubMed ID: 4148581
    [No Abstract]   [Full Text] [Related]  

  • 4. [Experimental design of a pilot study on amantadine in the extrapyramidal syndrome induced by neuroleptic drugs].
    Ferrari P; Robotti E; Nardini M
    Boll Chim Farm; 1972 Oct; 111(10):610-5. PubMed ID: 4566407
    [No Abstract]   [Full Text] [Related]  

  • 5. Antiparkinson medication in the treatment of extrapyramidal side effects: single of multiple daily doses?
    Neu C; Dimascio A; Demirgian E
    Curr Ther Res Clin Exp; 1972 May; 14(5):246-51. PubMed ID: 4623975
    [No Abstract]   [Full Text] [Related]  

  • 6. Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine.
    Kazamatsuri H; Chien CP; Cole JO
    Am J Psychiatry; 1973 Apr; 130(4):479-83. PubMed ID: 4570750
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of tardive dyskinesia. II. Short-term efficacy of dopamine-blocking agents haloperidol and thiopropazate.
    Kazamatsuri H; Chien C; Cole JO
    Arch Gen Psychiatry; 1972 Jul; 27(1):100-3. PubMed ID: 4555826
    [No Abstract]   [Full Text] [Related]  

  • 8. Neutralization of extrapyramidal side-effects with Methixene.
    Maller O; Heller S
    Dis Nerv Syst; 1971 Jun; 32(6):409-15. PubMed ID: 5570695
    [No Abstract]   [Full Text] [Related]  

  • 9. [Effects of neuroleptic withdrawal on the drug-induced extrapyramidal syndrome of chronic schizophrenia].
    Elie R; Gagnon MA; Gauthier R; Jéquier JC
    Union Med Can; 1975 Jun; 104(6):909-14. PubMed ID: 772906
    [No Abstract]   [Full Text] [Related]  

  • 10. [A new synthetic antiparkinsonian drug, tropatepine hydrochloride in extrapyramidal syndromes induced by neuroleptics].
    Lambert A; dachary JM; Marie C; Oules J; Pagot R; Sales M; Vauterin C
    Encephale; 1976; 2(2):115-21. PubMed ID: 776591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Present-day possibilities of relieving post-neuroleptic extrapyramidal symptoms].
    Wasik A
    Psychiatr Pol; 1973; 7(1):51-6. PubMed ID: 4715833
    [No Abstract]   [Full Text] [Related]  

  • 12. Methylphenidate in tardive dyskinesia.
    Fann WE; Davis JM; Wilson IC
    Am J Psychiatry; 1973 Aug; 130(8):922-4. PubMed ID: 4577471
    [No Abstract]   [Full Text] [Related]  

  • 13. [Amantadine and dexetimide in the treatment of parkinsonism].
    Hakkarainen H; Viukari M
    Duodecim; 1973 Jul; 89(21):1437-41. PubMed ID: 4586970
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical and ergotherapeutic evaluation of fluspirilene (R 6218), a long-acting injectable neuroleptic, in chronic psychotic patients.
    Tanghe A; Vereecken JL
    Psychiatr Neurol Neurochir; 1971; 74(5):379-89. PubMed ID: 5138128
    [No Abstract]   [Full Text] [Related]  

  • 15. Amantadine in extrapyramidal syndromes induced by neuroleptic drugs.
    Dencker SJ; Lindberg D; Malm U
    Nord Psykiatr Tidsskr; 1973; 27(1):31-4. PubMed ID: 4687749
    [No Abstract]   [Full Text] [Related]  

  • 16. Extrapyramidal side effects and oral haloperidol: an analysis of explanatory patient and treatment characteristics.
    Moleman P; Schmitz PJ; Ladee GA
    J Clin Psychiatry; 1982 Dec; 43(12):492-6. PubMed ID: 7161250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical trial of tropatepine chlorhydrate as a corrector of syndromes due to neuroleptics].
    Delaunay J; Guibert S
    Ann Med Psychol (Paris); 1976 Jan; 1(1):144-7. PubMed ID: 970819
    [No Abstract]   [Full Text] [Related]  

  • 18. [Clinical evaluation of amantadine in the treatment of extrapyramidal syndromes caused by neuroleptic drugs].
    Bukowczyk A; Wasik A; Horodnicki J
    Psychiatr Pol; 1974; 8(2):143-8. PubMed ID: 4830321
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of tardive dyskinesia. I. Clinical efficacy of a dopamine-depleting agent, tetrabenazine.
    Kazamatsuri H; Chien C; Cole JO
    Arch Gen Psychiatry; 1972 Jul; 27(1):95-9. PubMed ID: 4555831
    [No Abstract]   [Full Text] [Related]  

  • 20. An early clinical trial of lenperone (AHR 2277), a butyrophenone, in chronic schizophrenia.
    Simpson GM; Varga V
    Curr Ther Res Clin Exp; 1974 May; 16(5):477-82. PubMed ID: 4209063
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.